

Make **CONTRACE**  
part of their weight management journey

Now available  
in pharmacies!



## Introducing **CONTRACE**...

**CONTRACE** is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:










- $\geq 30 \text{ kg/m}^2$  (obese) or
- $\geq 27 \text{ kg/m}^2$  (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia).



**CONTRACE**  
recommended daily dose  
is two tablets BID<sup>1\*</sup>

In order to minimize the risk of seizures, the maximum recommended daily dose should not be exceeded.

**CONTRACE** dosing should be escalated according to the following schedule:

	 Morning	 Evening
<b>Week 1</b>		
<b>Week 2</b>		
<b>Week 3</b>		
<b>Week 4 and maintenance</b>		

Adapted from Product Monograph<sup>1</sup>

The **maximum** recommended dose is **32 mg / 360 mg per day** (two tablets twice daily).

Response to therapy should be evaluated after 12 weeks at the maintenance dosage. If a patient has not lost at least 5% of baseline body weight, discontinue **CONTRACE**, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.

Dosage adjustments are required in subjects with hepatic impairment (maximum dose 1 tablet in the morning in mild or moderate hepatic impairment) or renal impairment (maximum dose 2 tablets, one in the morning and one in the evening in moderate or severe renal impairment), and with concomitant use of CYP2B6 inhibitors (maximum dose 2 tablets, one in the morning and one in the evening). **CONTRACE** should not be taken with a high-fat meal. **The tablets should not be cut, chewed, or crushed.**

Consult the Product Monograph at [https://pdf.hres.ca/dpd\\_pm/00043849.PDF](https://pdf.hres.ca/dpd_pm/00043849.PDF) for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling **1-800-361-4261**.

\* Please consult the Product Monograph for complete dosage and administration information.

**Reference:** 1. **CONTRACE** Product Monograph. Valeant Canada LP, February 12, 2018.

